What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

M Preusser*, M Geurts, JA Hainfellner, MJ van den Bent

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

5 Citations (Scopus)
Original languageEnglish
Article numbernoad113
Pages (from-to)1915-1917
Number of pages3
JournalNeuro-Oncology
Volume25
Issue number11
Early online date21 Jul 2023
DOIs
Publication statusPublished - 1 Nov 2023

Bibliographical note

© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

Cite this